First it was the debt ceiling, then it was the fiscal cliff, and now we have sequestration. It seems that as the weeks go by, Washington is faced with one fiscal crisis after another, with little to no progress in making a meaningful dent in the ballooning deficit. No matter what your political leanings, this has been a frustrating process to watch unfold. For the oncology team (providers and payers alike), the process has also been filled with a fair amount of nail biting as Congress considers cost-cutting measures that could impact payment rates for oncologists, cancer hospitals, and manufacturers of oncology-related medications and diagnostics.